Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) – Pipeline Review, H2 2016’, provides in depth analysis on Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)

The report reviews Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics and enlists all their major and minor projects

The report assesses Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

CJ HealthCare Corp.

MorphoSys AG

Novartis AG

Vicore Pharma AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) Overview 6

Therapeutics Development 7

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Products under Development by Stage of Development 7

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Products under Development by Therapy Area 8

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Products under Development by Indication 9

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Products under Development by Companies 13

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Assessment 15

Assessment by Monotherapy/Combination Products 15

Assessment by Mechanism of Action 16

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Companies Involved in Therapeutics Development 22

CJ HealthCare Corp. 22

MorphoSys AG 23

Novartis AG 24

Vicore Pharma AB 25

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles 26

(amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

C-21 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

EMA-401 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

KDT-501 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

MOR-107 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

NP-6A - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant Projects 35

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Featured News & Press Releases 36

Sep 19, 2016: Lanthio Pharma Expands Management Team: Axel Mescheder M.D. Appointed Chief Medical Officer (CMO) of MorphoSys’s Dutch Lanthipeptide Subsidiary 36

Aug 01, 2016: Vicore Pharma is granted orphan drug designation for C21 for the treatment of IPF 36

Jun 30, 2016: New research data with C21 on diabetes 36

Jun 15, 2016: Prestigious award for UQ superstar scientist 37

Jun 13, 2016: Successful conclusion of the first Phase I study with C21 38

Feb 10, 2015: Spinifex Pharmaceuticals Enhances CMC Team With Two Senior Appointments 38

May 21, 2014: Lanthio Pharma receives Dutch Government loan of up to €3.6 million to develop novel therapy for lung fibrosis 39

Feb 05, 2014: Spinifex Pharmaceuticals’ Phase 2 Results Published in The Lancet Show EMA401 to be Effective in Reducing Pain in Postherpetic Neuralgia 39

Oct 18, 2013: Spinifex Pharmaceuticals' EMA401 Named One of the Top Ten Neuroscience Projects to Watch 40

Mar 27, 2013: Spinifex Pharma Receives AUD1.5m In R&D Tax Incentive For Research Activities Related To Discovery Of Treatments For Pain 41

Feb 18, 2013: Vicore Pharma Announces Publication Of Article In Nature 42

Dec 10, 2012: Spinifex Pharma Starts Phase II Proof-of-concept Trial Of EMA401 In Chemotherapy-induced Peripheral Neuropathy 42

Nov 15, 2012: Vicore Pharma Announces Presentation Of Study Results Of C21 In Pulmonary Hypertension At 2012 American Heart Meeting 43

Nov 15, 2012: Vicore Pharma Announces Publication Of Study Results Of C21 In Spinal Cord Injury In Journal Neurobiology Of Disease 44

Aug 28, 2012: Spinifex Pharma Announces Positive Phase II Results For EMA401 In Postherpetic Neuralgia 44

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Stage and Mechanism of Action, H2 2016 17

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by CJ HealthCare Corp., H2 2016 22

Pipeline by MorphoSys AG, H2 2016 23

Pipeline by Novartis AG, H2 2016 24

Pipeline by Vicore Pharma AB, H2 2016 25

Dormant Projects, H2 2016 35

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 15

Number of Products by Mechanism of Actions, H2 2016 16

Number of Products by Stage and Mechanism of Actions, H2 2016 16

Number of Products by Routes of Administration, H2 2016 18

Number of Products by Stage and Routes of Administration, H2 2016 18

Number of Products by Molecule Types, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports